# Eran Nadav

> Eran Nadav is a Series A investor at TPG Biotech (San Francisco) backing Biotechnology and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [TPG Biotech](https://shizune.co/investors/profile/tpg-biotech)
- Location: San Francisco, United States
- Total investments: 9
- Last investment: Sep 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eran-nadav-308b90132/

Eran Nadav is a Series A investor at TPG Biotech in San Francisco focused on Biotechnology and Medical. Dr. Nadav joined TPG Biotechnology in 2007 with a focus on global pharmaceuticals and biotechnology investments. Prior to this, Dr. Nadav served as Business Development Director at Eisai, Inc. in New Jersey for four years, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr. Nadav worked for the Israelioffice of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies, medical devices and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd., supporting the clinical development of Circadin®. Before his professional career and academic studies, Dr. Nadav served in the Israel Defense Forces for three years. Dr. Nadav holds a B.S. magna cum laude, M.S. magna cum laude and Ph.D. in biochemistry, as well as an MBA from Tel Aviv University. Dr. Nadav currently serves as Chairman of the Board for both Ultragenyx Pharmaceutical and Trevi Therapeutics, and he is a member of the Board of Directors at MacroGenics.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 33% |
| Medical | 2 | 22% |
| Health Care | 2 | 22% |
| Life Science | 2 | 22% |
| Therapeutics | 2 | 22% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 22% |
| Series B | 2 | 22% |
| Series C | 2 | 22% |
| Private Equity | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M | Series C | Sep 21, 2022 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M | Series B | Mar 01, 2021 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $47M | Series B | Jan 07, 2021 |  |
| Trevi Therapeutics | Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. |  | Series C | Jan 01, 2019 |  |
| Carisma Therapeutics | Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $53M | Series A | Jun 27, 2018 |  |
| Trevi Therapeutics | Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. | $30M | Series C | Jul 20, 2017 |  |
| Collegium Pharmaceutical | Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $50M | Private Equity | Mar 10, 2015 |  |
| Trevi Therapeutics | Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. |  | Series B |  |  |
| Trevi Therapeutics | Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. |  | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 6 deals together
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 4 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 4 deals together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 4 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 4 deals together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 3 deals together

## About TPG Biotech

VC Fund · San Francisco, United States

TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotechhas access to the broader resources of TPG.

5 contacts available at TPG Biotech.

| Name | Title | Profile |
| --- | --- | --- |
| Eran Nadav | Managing Director | https://shizune.co/investors/profile/eran-nadav |
| Jim Coulter | Co-Founder | https://shizune.co/investors/profile/jim-coulter |
| Kelvin L. Davis | Co-Founder | https://shizune.co/investors/profile/kelvin-l-davis |
| Kevin Lind | Lead Underwriter | https://shizune.co/investors/profile/kevin-lind |
| William S. Price | Co-Founder | https://shizune.co/investors/profile/william-s-price |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Eran Nadav invest in?

Eran Nadav invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eran Nadav last invest?

The most recent investment recorded for Eran Nadav closed in Sep 2022. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co